Loading…

Development and In Vitro Evaluation of Solid Dispersions As Strategy to Improve Albendazole Biopharmaceutical Behavior

Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole (ABZ) solubility and dissolution profiles. Methods: ABZ/poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical ABZ...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic delivery 2018-09, Vol.9 (9), p.623-638
Main Authors: Simonazzi, Analía, Cid, Alicia Graciela, Paredes, Alejandro Javier, Schofs, Laureano, Gonzo, Elio Emilio, Palma, Santiago Daniel, Bermúdez, José María
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: Solid dispersions using Poloxamer 407 as carrier were developed to improve albendazole (ABZ) solubility and dissolution profiles. Methods: ABZ/poloxamer solid dispersions were prepared, and dissolution profiles were mathematically modeled and compared with physical mixtures, pharmaceutical ABZ and a commercial formulation. Results: Poloxamer 407 increased exponentially ABZ solubility, in about 400% when 95% w/w of polymer compared with its absence. Solid dispersions initial dissolution rate was three to 20-fold higher than physical mixtures, the drug and the commercial formulation. All the solid dispersions required less than 2.2 min to reach an 80% of ABZ dissolution, while the commercial formulation needed around 40 min. Conclusion: Solid dispersions improved ABZ solubility and dissolution rate, which could result in a faster absorption and an increased bioavailability.
ISSN:2041-5990
2041-6008
DOI:10.4155/tde-2018-0037